Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management

详细信息    查看全文

• 作者：Christopher J. Chin ; Brian W. Rotenberg…
• 关键词：HHT ; Epistaxis ; Osler ; Weber ; Rendu ; Surgery
• 刊名：Journal of Otolaryngology - Head & Neck Surgery
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：45
• 期：1
• 全文大小：1,708 KB
• 参考文献：1.Guttmacher AE, Marchk DA, White RI. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;14:918–24.CrossRef
  2.Rendu HJ. Épistaxis répétées chez un sujet porteur de petits angiomes cutanés et muqueux. Bull Soc méd Hosp. Paris. 1896;13:731-3
  3.Osler W. On a family form of recurring epistaxis, associated with multiple telangiectases of the skin and mucous membranes. Bull Johns Hopkins Hosp. 1901;12:333–7.
  4.Weber FP. Multiple hereditary developmental angiomata (telangiectases) of the skin and mucous membranes associated with recurring haemorrhages. Lancet. 1907;2:160–2.
  5.Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med. 1999;245:31–9.PubMed CrossRef
  6.Westermann CJ, Rosina AF, De Vries V, de Coteau PA. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet A. 2003;116A:324–8.PubMed CrossRef
  7.Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91:66–7.PubMed CrossRef
  8.Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48:73–87.PubMed CrossRef
  9.Plauchu H, de Chadarévian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet. 1989;32:291–7.PubMed CrossRef
  10.Begbie ME, Wallace GMF, Shovlin CL. Hereditary heamorrhagic telangiectasia (Osler-Weber-Rendu yndrome): A view from the 21st century. Postgrad Med J. 2003;79:18–24.PubMed PubMedCentral CrossRef
  11.Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA, Kara N, et al. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope. 2010;120(4):838–43.PubMed CrossRef
  12.Gardiner Q. Topical management of anterior epistaxis: a national survey. J Laryngol Otol. 2009;123:91–5.PubMed CrossRef
  13.Reh DD, Hur K, Merlo CA. Efficacy of a topical sesame/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis. Laryngoscope. 2013;123:820–2.PubMed CrossRef
  14.Woolford TJ, Loke D, Bateman ND. The use of a nasal obturator in hereditary haemorrhagic telangiectasia: an alternative to Young's procedure. J Laryngol Otol. 2002;116:455–6.PubMed CrossRef
  15.Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial. Acta Med Scand. 1981;209:393–6.PubMed CrossRef
  16.Harrison DF. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope. 1982;92:314–20.PubMed CrossRef
  17.Jameson JJ, Cave DR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2004;114:705–9.PubMed CrossRef
  18.Yaniv E, Preis M, Hadar T, Shvero J, Haddad M. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope. 2009;119:284–8.PubMed CrossRef
  19.Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol. 2006;85:631–2.PubMed CrossRef
  20.Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009;360:2143–4.PubMed CrossRef
  21.Chen S, Karnezis T, Davidson TM. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011;121:644–6.PubMed CrossRef
  22.Simonds J, Miller F, Mandel J, Davidson TM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2009;119:988–92.PubMed CrossRef
  23.Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope. 2011;121:636–8.PubMed CrossRef
  24.Karnezis TT, Davidson TM. Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy. Laryngoscope. 2012;122:495–7.PubMed CrossRef
  25.Riss D, Burian M, Wolf A, Kranebitter V, Kaider A, Arnoldner C. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double-blind, randomized, placebo-controlled trial. Head Neck. 2015;37:783–7.PubMed CrossRef
  26.Olitsky SE. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am J Otolaryngol. 2012;33:375–6.PubMed CrossRef
  27.Epperla N, Brilliant MH, Vidaillet H. Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants. BMJ Case Rep. 2014; Feb 11.
  28.Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. 2010;16:420–8.PubMed CrossRef
  29.Penaloza A, Vekemans MC, Lambert C, Harmans C. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Blood Coagul Fibrinolysis. 2011;22:616–8.PubMed CrossRef
  30.Franchini M, Frattini F, Crestani S, Bonfanti C. Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide. J Thromb Thrombolysis. 2013;36:355–7.PubMed CrossRef
  31.Boyer H, Fernandes P, Duran O, Hunter D, Goding G. Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study. Int Forum Allergy Rhinol. 2011;1:319–23.PubMed CrossRef
  32.Boyer H, Fernandes P, Le C, Yueh B. Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia. Int Forum Allergy Rhinol. 2015;5:435–40.PubMed CrossRef
  33.Geisthoff UW, Seyfert UT, Kübler M, Bieg B, Plinkert PK, König J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014;134(3):565–71.PubMed CrossRef
  34.Gaillard S, Dupuis-Girod S, Boutitie F, Rivière S, Morinière S, Hatron PY, et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9):1494–502.PubMed CrossRef
  35.Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelan DH, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005;96(6):684–92.PubMed CrossRef
  36.de Gussem EM, Snijder RJ, Disch FJ, Zanen P, Westermann CJ, Mager JJ. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology. 2009;47(1):85–8.PubMed
  37.Ghaheri BA, Fong KJ, Hwang PH. The utility of bipolar electrocautery in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg. 2006;134:1006–9.PubMed CrossRef
  38.Jørgensen G, Lange B, Wanscher JH, Kjeldsen AD. Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia. Eur Arch Otorhinolaryngol. 2011;268:1765–70.PubMed CrossRef
  39.Ishibashi T, Takamatsu S. Hereditary hemorrhagic telangiectasis treated by the harmonic scalpel. Head Neck. 2003;25:333–6.PubMed CrossRef
  40.Luk L, Mace JC, Bhandarkar ND, Sautter NB. Comparison of electrosurgical plasma coagulation and potassium-titanyl-phosphate laser photocoagulation for treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Int Forum Allergy Rhinol. 2014;4:640–5.PubMed CrossRef
  41.Rotenberg BW, Noyek S, Chin CJ. Radiofrequency ablation for treatment of hereditary hemorrhagic telangiectasia lesions: “How I do it”. Am J Rhinol Allergy. 2015;29:226–7.PubMed CrossRef
  42.Joshi H, Woodworth BA, Carney AS. Coblation for epistaxis management in patients with hereditary haemorrhagic telangiectasia: a multicentre case series. J Laryngol Otol. 2011;125:1176–80.PubMed CrossRef
  43.Rimmer J, Lund VJ. A modified technique for septodermoplasty in hereditary hemorrhagic telangiectasia. Laryngoscope. 2014;124:67–9.PubMed CrossRef
  44.Harvey RJ, Kanagalingam J, Lund VJ. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol. 2008;22:182–7.PubMed CrossRef
  45.Lesnik GT, Ross DA, Henderson KJ, Joe JK, Leder SB, White Jr RI. Septectomy and septal dermoplasty for the treatment of severe transfusion-dependent epistaxis in patients with hereditary hemorrhagic telangiectasia and septal perforation. Am J Rhinol. 2007;21:312–5.PubMed CrossRef
  46.Trojanowski P, Jargiello T, Trojanowska A, Klatka J. Epistaxis in patients with hereditary hemorrhagic telangiectasia treated with selective arterial embolization. Acta Radiol. 2011;52(8):846–9.PubMed CrossRef
  47.Layton KF, Kallmes DF, Gray LA, Cloft HJ. Endovascular treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. AJNR Am J Neuroradiol. 2007;28(5):885–8.PubMed
  48.Richer SL, Geisthoff UW, Livada N, Ward PD, Johnson L, Mainka A, et al. The Young’s procedure for severe epistaxis from hereditary hemorrhagic telangiectasia. Am J Rhinol Allergy. 2012;26:401–4.PubMed CrossRef
  49.Ting JY, Remenschneider A, Holbrook EH. Management of severe epistaxis after Young’s procedure: a case report. Int Forum Allergy Rhinol. 2013;3:334–7.PubMed CrossRef
  
• 作者单位：Christopher J. Chin (1)
  Brian W. Rotenberg (2)
  Ian J. Witterick (1)
  
  1. Department of Otolaryngology-Head & Neck Surgery, University of Toronto, Room 413, Mount Sinai Hospital, 600 University Avenue, Toronto, ON, M5G 1X5, Canada
  2. Department of Otolaryngology-Head and Neck Surgery, Western University, Toronto, Canada
  
• 刊物主题：Medicine/Public Health, general;
• 出版者：BioMed Central
• ISSN：1916-0216

文摘

Patients with Hereditary Hemorrhagic Telangiectasia (HHT) frequently present with epistaxis. Up to 98 % of these patients will have epistaxis at some point in their life. There are multiple ways to deal with this problem, including conservative, medical and surgical options. We present a case and an update on the treatment options for HHT, with a focus on the newer and experimental techniques. Keywords HHT Epistaxis Osler-Weber-Rendu Surgery